Table 1 Baseline information of the enrolled studies
From: Network meta-analysis comparing efficacy of different strategies on medication-overuse headache
Study | Country | Participants | Age | Female Size | Sample Size | Intervention(s) vs Control | Withdrawal | Prevention or Intervention | Additional Education | Outcome | F/U |
|---|---|---|---|---|---|---|---|---|---|---|---|
Arab 2022 [36] | Iran | MOH3, CM, EM, TTH | 38 | 62% | 54 (27,27) | W+P+Nb vs W+P | Abrupt | GONB with 2% lidocaine and TA Oral prevention BB (12.9%), TPM (9%), AMT (29.6%), MTZ (22.8%), Others (25.7%) | No | MHDs | 12 weeks |
Carlsen 2018 [38] | Denmark | MOH3β, CM, EM, TTH | 47 | 75% | 53 (27, 26) | W+E vs R+E | Abrupt vs restriction | No | 8 lectures by nurses | MHDs | 8 weeks |
Carlsen 2020 [7] | Denmark | MOH3β, CM, EM, TTH | 44 | 79% | 102 (31,35, 36) | W+P vs P vs W | Abrupt | Oral prevention CDT (51.5%), AMT (19.6%), MT (13.6%), Others (28.8%) | No | MHDs | 8 weeks |
Diener 2007 [32] | Multicenter | MOH2, CM | 46 | 75% | 46 (23, 23) | P vs C | No | Oral prevention TPM (100%) | No | MMDs | 16 weeks |
Dodick 2020 | Multicenter | MO, EM, CM | 44 | 84% | 250 (77,173) | A vs C | No | Galcanezumab 120 mg SC monthly (100%) | No | MMDs | 24 weeks |
Hagen 2009 | Norway | MOH2, CM TTH | 41 | 60% | 56 (20, 17, 19) | W vs P vs C | Abrupt | Oral prevention CDT, BB, VPA, AMT, GBP (not mention %) | No | MHDs | 12 weeks |
Karadaş 2017 | Turkey | MOH3β | 37 | 75% | 70 (35, 35) | W+Nb vs W | Abrupt | GONB with 1%lidocaine | No | MHDs | 8 weeks |
Krymchantowski 2023 | Brazil | MOH3, CM | 44 | 73% | 172 (114, 58) | R+P+A vs R+P | Restriction | Oral prevention(s) TPM +NT (50%), VPA (29.7%), AT +NT (14.5%), AT +NT+FLN (5.8%) | No | MHDS | 12 weeks |
Mose 2020 | Denmark | MOH3β, CM, TTH, Cluster | 44 | 68% | 79 (40, 39) | W+P+E vs W+P | Abrupt | Oral prevention VPA (72%), TPM (8%), BB (8%), VP (6%), | 12 weeks education with 6 sessions | MHDs | 24 weeks after education |
Pijpers 2019 | Netherlands | MOH3β, CM | 45 | 76% | 179 (90,89) | W+B vs W | Abrupt | Botulinum toxin 155U (100%) | No | MHDs | 12 weeks |
Rossi 2006 | Italy | MOH2, CM | 44 | 85% | 79 (39,40) | W+P vs W | Abrupt | Oral prevention VPA (35.8%), AT (30.7%), AMT (25.6%), TPM (7.6%) | No | MHDs | 8 weeks |
Rossi 2013 | Italy | MOH2, CM | 46 | 80% | 92 (46,46) | W+P vs W | Abrupt | Oral prevention VPA (34.7), MT (23.9%), TPM (21.7%), AMT (19.5%) | No | MHDs | 10 weeks |
Sandrini 2011 | Italy | MOH2, CM | 49 | 80% | 56 (27,29) | W+B vs W | Abrupt | Botulinum toxin 100U (100%) | No | MHDs | 12 weeks |
Sarchielli 2014 | Italy | MOH2, EM | NA | 78% | 88 (44,44) | W+P vs W | Abrupt | Oral prevention VPA (100%) | No | MHDs | 12 weeks |
Schwedt 2022 | US | MOH3β, CM | 44 | 88% | 720 (361,359) | R+P vs P | Restriction | Headache prevention(s) TPM 25%, Botulinum toxin 14%, AMT 8.1%, Others (each less than 10%) | No | MHDs | 12 weeks |
Silberstein 2013 | Multicenter | MO, CM | 43 | 86% | 904 (445,459) | B vs C | No | Botulinum toxin 155-195U (100%) | No | MHDs | 24 weeks |